Fast-growing legaltech business Clarilis has raised a further £6m in a Series B investment to support its ongoing growth. The funding has come from Mercia’s Northern Venture Capital Trust Funds (VCTs), which were an existing investor in the business, and Gresham House Ventures, investing on behalf of the Baronsmead VCTs. The funding will assist the company’s
Investment Director, Jill Williams explains how important Mercia‘s core principles have accelerated our ESG journey and how best practice is vital moving forward. Many businesses will have some degree of track record in ‘making a difference’. At Mercia, we have a track record of positive impact within the UK’s regions. This is as much a
Mercia‘s Head of Portfolio Resourcing, Lisa Ward shares her thoughts on how to tackle the new, challenging landscape post-COVID-19. Remobilising a workforce, post-COVID-19, is no easy task because of the layered complexities that both operational and moral obligations bring to bear. Not only has the last 19 weeks of lock down wreaked havoc on organisations,
Mercia‘s Head of Portfolio Resources, Lisa Ward writes how businesses have been affected in many different ways due to the global COVID-19 pandemic and why a shift in mentality is on the horizon. As we anticipate the passing of the hurricane that is COVID-19, many businesses will be left to deal with the wake of
Mercia’s EIS fund principal Peter Dines discusses with Dr. Paul Mattick the recent sale of a portfolio company for 8x cost of investment. The pair also discussed: – The Mercia groups investment model – Our EIS is a venture capital investment with downside protection – This exit illustrates the potential when investing with Mercia
A biotech company which is developing new treatments for patients with serious spinal conditions has completed a £2.25m funding round led by Mercia Asset Management to help to continue its ground-breaking research and bring its first products to market. Locate Bio has secured the investment from Mercia’s own balance sheet, its EIS fund and the
Dr. Paul Mattick, Mercia‘s Head of Sales and Private Investor Relations, discusses how diversification and repeat investment impacts performance: – Mercia creates the most diverse EIS fund in the market – Diversification is important when investing in high-risk companies, to limit exposure to companies which will fail – Repeat investment enhances exposure to our winners
Specialist asset manager, Mercia Asset Management PLC, has sold its stake in The Native Antigen Company, a leading producer of infectious disease reagents, to global life sciences tools company LGC. The sale of The Native Antigen Company is for a total cash consideration of up to £18.0million. Mercia has supported The Native Antigen Company since
Mercia‘s Investment Director, Jill Williams speaks alongside Ward Hadaway to discuss supporting Mercia’s portfolio through COVID-19 and what issues and challenges that have been encountered.
Mercia‘s Investment Director, Jill Williams speaks alongside Ward Hadaway to discuss supporting Mercia’s portfolio through COVID-19 and what issues and challenges that have been encountered.